THE GOAL OF THIS RESEARCH IS TO DEVELOP A HIGHLY SENSITIVE AND SPECIFIC RADIOIMMUNOASSAY FOR LEUKOTRIENE E4 AND LEUKOTRIENE E4-N-ACETATE, TWO IMPORTANT METABOLITES OF LEUKOTRIENE C4 AND D4.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
4965
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Biomol Research Laboratories
Front & Lloyd Streets, Chester, PA, 19013
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ROBERT E ZIPKIN
PRINCIPAL INVESTIGATOR
(215) 874-1433
Business Contact:
() -
Research Institution:
n/a
Abstract
THE GOAL OF THIS RESEARCH IS TO DEVELOP A HIGHLY SENSITIVE AND SPECIFIC RADIOIMMUNOASSAY FOR LEUKOTRIENE E4 AND LEUKOTRIENE E4-N-ACETATE, TWO IMPORTANT METABOLITES OF LEUKOTRIENE C4 AND D4. THESE LEUKOTRIENES ARE POTENT BRONCO- AND CORONARY ARTERY VASOCONSTRICTORS, INCREASE VASCULAR PERMEABILITY, STIMULATE MUCUS SECRETION, AND CAUSE LONG-LASTING HYPOTENSION, THUS PLAYING A PATHOPHYSIOLOGICAL ROLE IN IMMEDIATE HYPERSENSITIVITY REACTIONS, INFLAMMATION, AND TISSUE TRAUMA. SPECIFIC AIMS OF THIS PROJECT INCLUDE: (1) PREPARATION OF A NUMBER OF LEUKOTRIENE E4 AND LEUKOTRI- ENE E4-N-AC-PROTEIN CONJUGATES HAVING VARIOUS MODES OF LEUKOTRIENE TO PROTEIN LINKAGE; (2) PRODUCTION OF ANTIBODIESTO EACH CONJUGATE BY IMMUNIZATION OF RABBITS; (3) COMPARISONOF THE ANTIBODIES AND SELECTION OF THOSE WITH HIGHEST SPECIFICITY AND SENSITIVITY; AND (4) PRODUCTION OF LEUKOTRIENE E4 AND E4-N-AC RADIOIMMUNOASSAY KITS FOR COMMERCIALIZATION. A LARGE NUMBER OF PHARMACEUTICAL COMPANIES ARE DEVELOPING SPECIFIC THERAPEUTIC AGENTS BASED ON LEUKOTRIENE INHIBITION AND/OR ANTAGONISM, AND THESE KITS ARE EXPECTED TO FIND WIDE APPLICATION.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government